Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues

Hepatology International

Volumn 2, Issue 2, 2008, Pages 163-178

  Leung, Nancy ^a,b  

^a ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chronic hepatitis B; Nucleos(t)ide analogues; Therapy

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; CLEVUDINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS VACCINE; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; TELBIVUDINE; TENOFOVIR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; SIDE EFFECT; VIRUS LOAD;

EID: 51049114985     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-008-9061-6     Document Type: Review

References (135)

1. 1. BS Blumberg BJ Gerstley DA Hungerford T London AI Sutnick 1967 A serum antigen (Australia Antigen) in Down’s syndrome, leukemia, and hepatitis Ann Intern Med 66 5 924 31 4225883 1:STN:280:DyaF2s7mtFWktQ%3D%3D Blumberg BS, Gerstley BJ, Hungerford DA, London T, Sutnick AI. A serum antigen (Australia Antigen) in Down’s syndrome, leukemia, and hepatitis. Ann Intern Med. 1967;66(5):924–31.
2. 2. D Lavanchy 2004 Hepatitis B virus epidemiology, disease burden, treatment and current and emerging prevention and control measures J Viral Hepatol 11 97 107 1:STN:280:DC%2BD2c7gs1Whug%3D%3D Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment and current and emerging prevention and control measures. J Viral Hepatol. 2004;11:97–107.
3. 3. I Merican R Guan D Amarapuka MJ Alexander A Chutaputti RN Chien 2000 Chronic hepatitis B virus infection in Asian countries J Gastroenterol Hepatol 15 12 1356 61 11197043 1:STN:280:DC%2BD3M7jvFCitw%3D%3D Review Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol. 2000;15(12):1356–61. Review.
4. 4. MF Yuen CK Hui CC Cheng CH Wu YP Lai CL Lai 2001 Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications Hepatology 34 139 45 11431745 1:CAS:528:DC%2BD3MXltlKjsL4%3D Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology. 2001;34:139–45.
5. 5. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update.1. Liver Int. 2005;25(3):472–89.
6. 6. UH Iloeje HI Yang J Su CL Jen SL Chen 2006 Predicting cirrhosis risk based on the level of circulating hepatitis B viral load Gastroenterology 130 3 678 86 16530509 Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678–86.
7. 7. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65–73.
8. 8. Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5(8):921–31.
9. 9. G Chen W Lin F Shen UH Iloeje WT London AA Evans 2006 Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study Am J Gastroenterol 101 8 1797 803 16817842 Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol. 2006;101(8):1797–803.
10. 10. CL Lai RN Chien NWY Leung TT Chang R Guan DI Tai 1998 A one-year trial of lamivudine for chronic hepatitis B N Engl J Med 339 2 61 8 9654535 1:CAS:528:DyaK1cXkvVSqtbY%3D (see Editorial) Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med. 1998;339(2):61–8 (see Editorial).
11. 11. NC Tassopoulos R Volpes G Pastore J Heathcote M Buti RD Goldin 1999 Efficacy of lamivudine in patients with hepatitis Be antigen-negative/hepatitis B virus DNA-positive (precore) chronic hepatitis B Hepatology 29 889 96 10051494 1:CAS:528:DyaK1MXhvFyjsLs%3D Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, et al. Efficacy of lamivudine in patients with hepatitis Be antigen-negative/hepatitis B virus DNA-positive (precore) chronic hepatitis B. Hepatology. 1999;29:889–96.
12. 12. JL Dienstag ER Schiff TL Wright 1999 Lamivudine as initial treatment of chronic hepatitis B in United States N Engl J Med 341 1256 63 10528035 1:CAS:528:DyaK1MXnt1Cqs78%3D Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment of chronic hepatitis B in United States. N Engl J Med. 1999;341:1256–63.
13. 13. RN Chien YF Liaw M Atkins 1999 Pretherapy alanine transaminase level as a determinant for hepatitis Be antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group Hepatology 30 3 770 4 10462384 1:CAS:528:DyaK1MXmtVSkt7Y%3D Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis Be antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology. 1999;30(3):770–4.
14. 14. N Leung 2002 Clinical experience with lamivudine Semin Liver Dis 22 Suppl 1 15 22 12447725 1:CAS:528:DC%2BD38XpsFKmu70%3D Leung N. Clinical experience with lamivudine. Semin Liver Dis. 2002;22(Suppl 1):15–22.
15. 15. SK Yoon JW Jang CW Kim SH Bae JY Choi SW Choi 2005 Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion Intervirology 48 6 341 9 16024938 1:CAS:528:DC%2BD2MXmt1Gntbw%3D Yoon SK, Jang JW, Kim CW, Bae SH, Choi JY, Choi SW, et al. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion. Intervirology. 2005;48(6):341–9.
16. 16. R Guan YF Liaw NWY Leung 2000 Durable HbeAg response in Chinese patients treated with lamivudine J Gastroenterol Hepatol 15 Suppl 1106 Guan R, Liaw YF, Leung NWY, et al. Durable HbeAg response in Chinese patients treated with lamivudine. J Gastroenterol Hepatol. 2000;15(Suppl):I106.
17. 17. HL Chan H Wang J Niu AM Chim JJ Sung 2007 Two-year lamivudine treatment for hepatitis Be antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial Antivir Ther 12 3 345 53 17591024 1:CAS:528:DC%2BD2sXntFOrsbc%3D Chan HL, Wang H, Niu J, Chim AM, Sung JJ. Two-year lamivudine treatment for hepatitis Be antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther. 2007;12(3):345–53.
18. 18. RN Chien YF Liaw 2006 Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan Antivir Ther 11 7 947 52 17302259 1:CAS:528:DC%2BD28Xhtlajs7vI Chien RN, Liaw YF. Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan. Antivir Ther. 2006;11(7):947–52.
19. 19. AS Lok CL Lai N Leung GB Yao ZY Cui ER Schiff 2003 Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 6 1714 22 14724824 1:CAS:528:DC%2BD2cXhtVOrug%3D%3D Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125(6):1714–22.
20. 20. CL Lai J Dienstag E Schiff NW Leung M Atkins C Hunt 2003 Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B Clin Infect Dis. 36 6 687 96 12627352 1:CAS:528:DC%2BD3sXjtVKqtbk%3D Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36(6):687–96.
21. 21. MF Yuen CL Lai 2007 Prediction of treatment outcomes for lamivudine J Gastroenterol Hepatol 22 7 964 5 17608839 Yuen MF, Lai CL. Prediction of treatment outcomes for lamivudine. J Gastroenterol Hepatol. 2007;22(7):964–5.
22. 22. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521–31.
23. 23. SK Sarin BS Sandhu BC Sharma M Jain J Singh V Malhotra 2004 Beneficial effects of ‘lamivudine pulse’ therapy in HBeAg-positive patients with normal ALT J Viral Hepatol 11 6 552 8 1:STN:280:DC%2BD2crjtFaqtw%3D%3D Sarin SK, Sandhu BS, Sharma BC, Jain M, Singh J, Malhotra V. Beneficial effects of ‘lamivudine pulse’ therapy in HBeAg-positive patients with normal ALT. J Viral Hepatol. 2004;11(6):552–8.
24. 24. S Manolakopoulos S Bethanis J Elefsiniotis S Karatapanis C Triantos G Sourvinos 2006 Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome Aliment Pharmacol Ther 23 6 787 95 16556181 1:CAS:528:DC%2BD28XjslGmt7o%3D Manolakopoulos S, Bethanis S, Elefsiniotis J, Karatapanis S, Triantos C, Sourvinos G, et al. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome. Aliment Pharmacol Ther. 2006;23(6):787–95.
25. 25. JJ Sung ML Wong S Bowden CT Liew AY Hui VW Wong 2005 Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy Gastroenterology 128 7 1890 7 15940624 1:CAS:528:DC%2BD2MXlvFKlsLc%3D Sung JJ, Wong ML, Bowden S, Liew CT, Hui AY, Wong VW, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology. 2005;128(7):1890–7.
26. 26. HLY Chan VW Wong AML Tse AML Chim HY Chan 2007 Serum hepatitis B surface antigen (HBsAg) level can reflect hepatitis B virus in the liver and predict treatment response J Hepatol 17 Suppl 46 S186 Chan HLY, Wong VW, Tse AML, Tse CH, Chim AML, Chan HY, et al. Serum hepatitis B surface antigen (HBsAg) level can reflect hepatitis B virus in the liver and predict treatment response. J Hepatol. 2007;17(Suppl 46):S186.
27. 27. V Thakur SK Sarin S Rehman RC Guptan SN Kazim S Kumar 2005 Role of HBV genotype in predicting response to lamivudine therapy in patients with chronic hepatitis B Indian J Gastroenterol 24 1 12 5 15778519 1:STN:280:DC%2BD2M7ks1SjtA%3D%3D Thakur V, Sarin SK, Rehman S, Guptan RC, Kazim SN, Kumar S. Role of HBV genotype in predicting response to lamivudine therapy in patients with chronic hepatitis B. Indian J Gastroenterol. 2005;24(1):12–5.
28. 28. MF Yuen E Sablon E Libbrecht H Velde Van De DK Wong J Fung 2006 Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment Antivir Ther 11 6 779 86 17310822 1:CAS:528:DC%2BD28XhtFKgsLjK Yuen MF, Sablon E, Libbrecht E, Van De Velde H, Wong DK, Fung J, et al. Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment. Antivir Ther. 2006;11(6):779–86.
29. 29. JJ Chen CY Lin MJ Sheu HT Kuo CS Sun LY Tang 2006 Poor response to 18-month lamivudine monotherapy in chronic hepatitis B patients with IgM anti-HBc and acute exacerbation Aliment Pharmacol Ther 23 1 85 90 16393284 Chen JJ, Lin CY, Sheu MJ, Kuo HT, Sun CS, Tang LY, et al. Poor response to 18-month lamivudine monotherapy in chronic hepatitis B patients with IgM anti-HBc and acute exacerbation. Aliment Pharmacol Ther. 2006;23(1):85–90.
30. 30. Nakamuta M, Kotoh K, Tanabe Y, Kajiwara E, Shimono J, Masumoto A, et al. Body surface area is an independent factor contributing to the effects of lamivudine treatment. Hepatol Res. 2005;31(1):13–7.
31. 31. RN Chien CT Yeh SL Tsai CM Chu YF Liaw 2003 Determinants for sustained HBeAg response to lamivudine therapy Hepatology 38 5 1267 73 14578866 1:CAS:528:DC%2BD3sXpsVOnt7w%3D Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology. 2003;38(5):1267–73.
32. 32. N Shinkai Y Tanaka E Orito K Ito T Ohno N Hirashima et al. 2006 Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection Hepatol Res 36 4 272 6 16971173 1:CAS:528:DC%2BD28Xht1ersLvN Shinkai N, Tanaka Y, Orito E, Ito K, Ohno T, Hirashima N, et al. Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection. Hepatol Res. 2006;36(4):272–6.
33. 33. JW Jang SH Bae JY Choi CW Kim NI Han JY Han 2006 Early virological response predicts outcome during extended lamivudine retreatment in patients with chronic hepatitis B who relapsed after initial HBeAg responses J Gastroenterol Hepatol 21 2 384 91 16509863 1:CAS:528:DC%2BD28XjvFyrtbw%3D Jang JW, Bae SH, Choi JY, Kim CW, Han NI, Han JY, et al. Early virological response predicts outcome during extended lamivudine retreatment in patients with chronic hepatitis B who relapsed after initial HBeAg responses. J Gastroenterol Hepatol. 2006;21(2):384–91.
34. 34. JW Shin NH Park JH Park JH Park ID Jeong SJ Bang 2005 Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B J Viral Hepatol 12 4 393 7 1:STN:280:DC%2BD2MzjsV2itw%3D%3D Shin JW, Park NH, Park JH, Park JH, Jeong ID, Bang SJ, et al. Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B. J Viral Hepatol. 2005;12(4):393–7.
35. 35. CM Hunt JM McGill MI Allen 2000 Clinical relevance of hepatitis B mutations Hepatology 31 5 1037 44 10796877 1:CAS:528:DC%2BD3cXjtlyltb0%3D Hunt CM, McGill JM, Allen MI, et al. Clinical relevance of hepatitis B mutations. Hepatology. 2000;31(5):1037–44.
36. 36. AJ Thompson A Ayres L Yuen A Bartholomeusz DS Bowden DM Iser 2007 Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors J Gastroenterol Hepatol 22 7 1078 85 17608854 1:CAS:528:DC%2BD2sXpsFarsb4%3D Thompson AJ, Ayres A, Yuen L, Bartholomeusz A, Bowden DS, Iser DM, et al. Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol. 2007;22(7):1078–85.
37. 37. Leung NWY, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis e antigen seroconversion rates: results after three years of therapy. Hepatology. 2001;33(6):1527–32.
38. 38. SN Kazim R Chauhan BC Das SK Sarin 2006 Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy J Gastroenterol Hepatol 21 10 1525 32 16928212 1:CAS:528:DC%2BD28Xht1Sgt77E Kazim SN, Chauhan R, Das BC, Sarin SK. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy. J Gastroenterol Hepatol. 2006;21(10):1525–32.
39. 39. HL Chan VW Wong CH Tse AM Chim HY Chan GL Wong 2007 Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B Aliment Pharmacol Ther 25 8 891 8 17402992 1:CAS:528:DC%2BD2sXls1Gmtbs%3D 10.1111/j.1365-2036.2007.03272.x Chan HL, Wong VW, Tse CH, Chim AM, Chan HY, Wong GL, et al. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment Pharmacol Ther. 2007;25(8):891–8.
40. 40. MG Peters H Hann Hw P Martin EJ Heathcote P Buggisch R Rubin 2004 Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B Gastroenterology 126 1 91 101 14699491 1:CAS:528:DC%2BD2cXhtFGntLo%3D Peters MG, Hann Hw H, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2004;126(1):91–101.
41. 41. R Perrillo HW Hann D Mutimer B Willems N Leung WM Lee 2004 Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus Gastroenterology 126 1 81 90 14699490 1:CAS:528:DC%2BD2cXhtFGntL0%3D Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004;126(1):81–90.
42. 42. P Lampertico A Marzano M Levrero 2007 Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B J Hepatol 46 Suppl 1 S191 Lampertico P, Marzano A, Levrero M, et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2007;46(Suppl 1):S191.
43. 43. HI Lee JH Lee WY Tak JS Hwang SH Bae TH Lee 2007 Overlapping of lamivudine and adefovir before switching to adefovir monotherapy in lamivudine resistant chronic hepatitis B: is it necessary? J Hepatol 46 Suppl 1 S191 Lee HI, Lee JH, Tak WY, Hwang JS, Bae SH, Lee TH, et al. Overlapping of lamivudine and adefovir before switching to adefovir monotherapy in lamivudine resistant chronic hepatitis B: is it necessary? J Hepatol. 2007;46(Suppl 1):S191.
44. 44. van der Poorten D, Prakoso E, Khoo TL, Ngu MC, McCaughan GW, Strasser SI, et al. Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. J Gastroenterol Hepatol. 2007;22(9):1500–6.
45. 45. YF Liaw CM Lee RN Chien CT. Yeh 2006 Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis J Viral Hepatol 13 4 250 5 Liaw YF, Lee CM, Chien RN, Yeh CT. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J Viral Hepatol. 2006;13(4):250–5.
46. 46. C Hézode S Chevaliez M Bouvier-Alias F Roudot-Thoraval R Brillet ES Zafrani 2007 Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily J Hepatol 46 5 791 6 17321635 Hézode C, Chevaliez S, Bouvier-Alias M, Roudot-Thoraval F, Brillet R, Zafrani ES, et al. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. J Hepatol. 2007;46(5):791–6.
47. 47. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130(7):2039–49.
48. 48. DJ Tenney RE Rose CJ Baldick SM Levine KA Pokornowski AW Walsh 2007 Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present Antimicrob Agents Chemother 51 3 902 11 17178796 1:CAS:528:DC%2BD2sXis12jsrk%3D Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother. 2007;51(3):902–11.
49. 49. S Villet A Ollivet C Pichoud L Barraud JP Villeneuve C Trepo 2007 Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient J Hepatol 46 3 531 8 17239478 1:CAS:528:DC%2BD2sXhtlCmur8%3D Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trepo C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol. 2007;46(3):531–8.
50. 50. PL Tseng SN Lu HD Tung JH Wang CS Changchien CM. Lee 2005 Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis J Viral Hepatol 12 4 386 92 Tseng PL, Lu SN, Tung HD, Wang JH, Changchien CS, Lee CM. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. J Viral Hepatol. 2005;12(4):386–92.
51. 51. RJ Fontana 2003 Management of patients with decompensated HBV cirrhosis Semin Liver Dis 23 1 89 100 12616454 1:CAS:528:DC%2BD3sXisFamtrY%3D (review) Fontana RJ. Management of patients with decompensated HBV cirrhosis. Semin Liver Dis. 2003;23(1):89–100 (review).
52. 52. Saab S, Dong MH, Joseph TA, Tong MJ. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology. 2007;46(4):1049–56.
53. 53. YH Li YF He WQ Jiang FH Wang XB Lin L Zhang 2006 Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma Cancer 106 6 1320 5 16470607 1:CAS:528:DC%2BD28XjtVCrsbw%3D Li YH, He YF, Jiang WQ, Wang FH, Lin XB, Zhang L, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer. 2006;106(6):1320–5.
54. 54. EM Sokal DA Kelly J Mizerski IB Badia JA Areias KB Schwarz 2006 Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B Hepatology 43 2 225 32 16440364 1:CAS:528:DC%2BD28XhvVSgu7Y%3D Sokal EM, Kelly DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology. 2006;43(2):225–32.
55. 55. F Ozgenç C Arikan RY Sertoz D Nart S Aydogdu RV. Yagci 2004 Effect of long-term lamivudine in chronic hepatitis B virus-infected children Antivir Ther 9 5 729 32 15535410 Ozgenç F, Arikan C, Sertoz RY, Nart D, Aydogdu S, Yagci RV. Effect of long-term lamivudine in chronic hepatitis B virus-infected children. Antivir Ther. 2004;9(5):729–32.
56. 56. A Yilmaz M Akcam T Gelen R. Artan 2007 Lamivudine and high-dose interferon alpha 2a combination treatment in naïve HBeAg-positive immunoactive chronic hepatitis B in children: an East Mediterranean center’s experience Eur J Pediatr 166 3 195 9 16944240 1:CAS:528:DC%2BD2sXitlCltbs%3D Yilmaz A, Akcam M, Gelen T, Artan R. Lamivudine and high-dose interferon alpha 2a combination treatment in naïve HBeAg-positive immunoactive chronic hepatitis B in children: an East Mediterranean center’s experience. Eur J Pediatr. 2007;166(3):195–9.
57. 57. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129(2):528–36.
58. 58. HL Chan VW Wong AM Chim PC Choi HY Chan AY Hui 2007 Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B Antivir Ther 12 5 815 23 17713165 1:CAS:528:DC%2BD2sXpslOlsLY%3D Chan HL, Wong VW, Chim AM, Choi PC, Chan HY, Hui AY, et al. Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B. Antivir Ther. 2007;12(5):815–23.
59. 59. Sarin SK, Sood A, Kumar M, Arora A, Amrapurkar D, Sharma BC, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol. 2007;102(1):96–104.
60. 60. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348(9):808–16.
61. 61. T Chang ML Shiffman M Tong 2006 Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B Gastroenterology 130 A-846 [#T1844] Chang T, Shiffman ML, Tong M, et al. Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B. Gastroenterology. 2006;130:A-846 [#T1844].
62. 62. M Zeng KF. Barker 2006 A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B Hepatology 44 1 108 16 16799983 1:CAS:528:DC%2BD28XnsFWjt7Y%3D Zeng M, Barker KF. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology. 2006;44(1):108–16.
63. 63. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis Be antigen-negative chronic hepatitis B. N Engl J Med. 2003 Feb 27;348(9):800–7. Erratum in: N Engl J Med. 2003;348(12):1192.
64. 64. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131(6):1743–51.
65. 65. SJ Hadziyannis V Sevastianos IN Rapti NC. Tassopoulos 2006 Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg negative chronic hepatitis B Hepatology 44 Suppl 4 231A Hadziyannis SJ, Sevastianos V, Rapti IN, Tassopoulos NC. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg negative chronic hepatitis B. Hepatology. 2006;44(Suppl 4):231A.
66. 66. A Laras A Kostamena SJ. Hadziyannis 2007 HBV cccDNA pregenomic RNA and total HBV DNA levels in the liver of HBeAg-negative CHB patients under long term antiviral therapy J Hepatol 46 Suppl 1 S28 Laras A, Kostamena A, Hadziyannis SJ. HBV cccDNA pregenomic RNA and total HBV DNA levels in the liver of HBeAg-negative CHB patients under long term antiviral therapy. J Hepatol. 2007;46(Suppl 1):S28.
67. 67. C Westland W Delaney IV H Yang SS Chen P Marcellin S Hadziyannis 2003 Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1 Gastroenterology 125 1 107 16 12851876 1:CAS:528:DC%2BD3sXmtVWqtbc%3D Westland C, Delaney W IV, Yang H, Chen SS, Marcellin P, Hadziyannis S, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology. 2003;125(1):107–16.
68. 68. Lim S, Marcellin P, Tassopoulos N, Hadziyannis S, Chang T, Tong M, et al. Effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. Aliment Pharmacol Ther. 2007;26(10):1419–28.
69. 69. O Schildgen H Sirma A Funk 2006 Variant of hepatitis B virus with primary resistance to adefovir N Engl J Med 354 1807 12 16641397 1:CAS:528:DC%2BD28XjvVWgtr0%3D Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med. 2006;354:1807–12.
70. 70. Kim DY, Lee JH, Lee DH, et al. Occurrence of primary adefovir resistance mutation in hepatitis B patients with YMDD mutation and lamivudine resistance. Gastroenterology. 2006;130:A–846 [#T1843].
71. 71. M Buti I Elefsiniotis R Jardi V Vargas F Rodriguez-Frias M Schapper 2007 Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients J Hepatol 47 3 366 72 17561304 1:CAS:528:DC%2BD2sXosF2ku7s%3D Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-Frias F, Schapper M, et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol. 2007;47(3):366–72.
72. 72. JE. Yeon 2006 Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil Gut 55 10 1488 95 16461777 1:CAS:528:DC%2BD28XhtFeht7rJ Yeon JE. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut. 2006;55(10):1488–95.
73. 73. CH Chen JH Wang CM Lee CH Hung TH Hu JC Wang 2006 Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil Antivir Ther 11 6 771 8 17310821 1:CAS:528:DC%2BD28XhtFKgsLjJ Chen CH, Wang JH, Lee CM, Hung CH, Hu TH, Wang JC, et al. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. Antivir Ther. 2006;11(6):771–8.
74. 74. J Fung CL Lai JC Yuen DK Wong Y Tanaka M Mizokami 2007 Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population Antivir Ther 12 1 41 6 17503746 1:CAS:528:DC%2BD2sXjs1GntrY%3D Fung J, Lai CL, Yuen JC, Wong DK, Tanaka Y, Mizokami M, et al. Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. Antivir Ther. 2007;12(1):41–6.
75. 75. SK Fung HB Chae RJ Fontana H Conjeevaram J Marrero K Oberhelman 2006 Virologic response and resistance to adefovir in patients with chronic hepatitis B J Hepatol 44 2 283 90 16338024 1:CAS:528:DC%2BD28Xktl2qsA%3D%3D Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol. 2006;44(2):283–90.
76. 76. S Kaymakoglu R Idilman E Ahishali FO Onder M Bektas S Badur 2007 High baseline HBV-DNA is linked to the emergence of adefovir resistance in lamivudine resistant patients J Hepatol 46 Suppl 1 S189 Kaymakoglu S, Idilman R, Ahishali E, Onder FO, Bektas M, Badur S, et al. High baseline HBV-DNA is linked to the emergence of adefovir resistance in lamivudine resistant patients. J Hepatol. 2007;46(Suppl 1):S189.
77. 77. YF Liaw 2007 Rescue therapy for lamivudine-resistant chronic hepatitis B: when and how? Hepatology 45 2 266 8 17256763 1:CAS:528:DC%2BD2sXisVKgurc%3D [Comment in: Hepatology 2007;45(2):307–13.] Liaw YF. Rescue therapy for lamivudine-resistant chronic hepatitis B: when and how? Hepatology. 2007;45(2):266–8. [Comment in: Hepatology. 2007;45(2):307–13.]
78. 78. E Schiff CL Lai P Neuhaus 2006 Safety and efficacy of adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B undergoing liver transplantation Gastroenterology 130 A-765 [abstract #480] Schiff E, Lai CL, Neuhaus P, et al. Safety and efficacy of adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B undergoing liver transplantation. Gastroenterology. 2006;130:A-765 [abstract #480].
79. 79. E Schiff CL Lai S Hadziyannis P Neuhaus N Terrault M Colombo 2007 Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results Liver Transpl 13 3 349 60 17326221 Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 2007;13(3):349–60.
80. 80. F Bommel van 2006 Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy Hepatology 44 2 318 25 16871563 [Comment in: Hepatology 2006;44(2):309–13.] van Bommel F. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006;44(2):318–25. [Comment in: Hepatology. 2006;44(2):309–13.]
81. 81. TT Chang CL Lai 2006 Hepatitis B virus with primary resistance to adefovir New Engl J Med 355 34 322 3 16855278 1:CAS:528:DC%2BD28XmvF2ru7Y%3D (author reply 323) [Comment in: N Engl J Med 2006;354(17):1807–12.] Chang TT, Lai CL. Hepatitis B virus with primary resistance to adefovir. New Engl J Med. 2006;355(34):322–3 (author reply 323). [Comment in: N Engl J Med. 2006;354(17):1807–12.]
82. 82. SA Santos AJ Uriel JS Park J Lucas D Carriero D Jaffe 2006 Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen Eur J Gastroenterol Hepatol 18 12 1247 53 17099372 1:CAS:528:DC%2BD28XhtFymtLrK Santos SA, Uriel AJ, Park JS, Lucas J, Carriero D, Jaffe D, et al. Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen. Eur J Gastroenterol Hepatol. 2006;18(12):1247–53.
83. 83. E Sokal D Kelly S Wirth J Mizerski B Lu K Kleber 2004 The paharmacokinetics (PK) and safety of a single dose of adefovir dipivoxil (ADV) in children and adolescents aged 2–17) with chronic hepatitis B J Heptol 40 Suppl 1 132 Sokal E, Kelly D, Wirth S, Mizerski J, Lu B, Kleber K, et al. The paharmacokinetics (PK) and safety of a single dose of adefovir dipivoxil (ADV) in children and adolescents aged 2–17) with chronic hepatitis B. J Heptol. 2004;40(Suppl 1):132.
84. 84. F Perez-Roldan P Gonzalez-Carro MC. Villafanez-Garcia 2005 Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection N Engl J Med 352 3 310 1 15659742 1:CAS:528:DC%2BD2MXmvVeksQ%3D%3D Perez-Roldan F, Gonzalez-Carro P, Villafanez-Garcia MC. Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N Engl J Med. 2005;352(3):310–1.
85. 85. K Wursthorn M Lutgehetmann M Dandri T Volz P Buggisch B Zollner 2006 Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B Hepatology 44 3 675 84 16941693 1:CAS:528:DC%2BD28XhtVeqt7bM Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44(3):675–84.
86. 86. RJ Colonna EV Genovesi I Medina 2001 Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in woodchuck model of chronic hepatitis infection J Infect Dis 184 1236 45 Colonna RJ, Genovesi EV, Medina I, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in woodchuck model of chronic hepatitis infection. J Infect Dis. 2001;184:1236–45.
87. 87. PL Marion FH Salazar MA Winters RJ. Colonno 2002 Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication Antimicrob Agents Chemother 46 1 82 8 11751115 1:CAS:528:DC%2BD38XjtVaqtw%3D%3D Marion PL, Salazar FH, Winters MA, Colonno RJ. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother. 2002;46(1):82–8.
88. 88. Langley DR, Walsh AW, Baldick CJ, Eggers BJ, Rose RE, Levine SM, et al. Inhibition of hepatitis B virus polymerase by entecavir. J Virol. 2007;81(8):3992–4001.
89. 89. A Billich 2001 Entecavir (Bristol-Myers Squibb) Curr Opin Investig Drugs 2 5 617 21 11569933 1:CAS:528:DC%2BD3MXktlyjt7w%3D (review) Billich A. Entecavir (Bristol-Myers Squibb). Curr Opin Investig Drugs. 2001;2(5):617–21 (review).
90. 90. LM Wolters BE Hansen HG Niesters D DeHertogh RA de Man 2002 Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B J Hepatol 37 1 137 44 12076873 1:CAS:528:DC%2BD38XksFyls7s%3D Erratum in: J Hepatol 2002;37(5):708 Wolters LM, Hansen BE, Niesters HG, DeHertogh D, de Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol. 2002;37(1):137–44. Erratum in: J Hepatol. 2002;37(5):708.
91. 91. RA de Man LM Wolters F Nevens D Chua M Sherman CL Lai 2001 Safety and efficacy of oral entecavir given for 28 days in patients with CHB Hepatology 34 3 578 82 11526545 1:CAS:528:DC%2BD3MXmvV2kt7k%3D de Man RA, Wolters LM, Nevens F, Chua D, Sherman M, Lai CL, et al. Safety and efficacy of oral entecavir given for 28 days in patients with CHB. Hepatology. 2001;34(3):578–82.
92. 92. CL Lai M Rosmawati J Lao H Vlierberghe Van FH Anderson N Thomas 2002 Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection Gastroenterology 123 6 1831 8 12454840 1:CAS:528:DC%2BD38Xps1yktbw%3D Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology. 2002;123(6):1831–8.
93. 93. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001–10.
94. 94. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354(10):1011–20. Erratum in: N Engl J Med. 2006;354(17):1863.
95. 95. Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology. 2005;129(4):1198–209.
96. 96. DK Wong MF Yuen VW Ngai J Fung CL. Lai 2006 One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels Antivir Ther 11 7 909 16 17302253 1:CAS:528:DC%2BD28Xhtlajs7rN Wong DK, Yuen MF, Ngai VW, Fung J, Lai CL. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther. 2006;11(7):909–16.
97. 97. Leung N, Peng C-Y, Sollano J, Lesmana L, Yuen M-F, Jeffers L, Hann H-W, et al. Entecavir results in higher HBV DNA reduction vs adefovir in chronically infected HBeAg(+) antiviral-naive Adults: 24 WK Results (E.A.R.L.Y. Study). Hepatology. 2006;44(Suppl 4):554A.
98. 98. TT Chang YC Chao S Kaymakoglu H Cheinquer M Pessoa RG Gish 2006 Entecavir maintained virological suppression through three years of treatment in antiviral-naïve HBEAG(+) patients (ETV 022/901) Hepatology 44 Suppl 4 229A Chang TT, Chao YC, Kaymakoglu S, Cheinquer H, Pessoa M, Gish RG, et al. Entecavir maintained virological suppression through three years of treatment in antiviral-naïve HBEAG(+) patients (ETV 022/901). Hepatology. 2006;44(Suppl 4):229A.
99. 99. S Han TT Chan YC Chao SK Yoon RG Gish H Cheinquer 2007 Four-year entecavir treatment in nucleoside-naïve HBeAg (+) patients: results from studies ETV-022 and-901 Hepatology 46 4 Suppl 1 654A Han S, Chan TT, Chao YC, Yoon SK, Gish RG, Cheinquer H, et al. Four-year entecavir treatment in nucleoside-naïve HBeAg (+) patients: results from studies ETV-022 and-901 Hepatology. 2007;46(4 Suppl 1):654A.
100. 100. GB Yao M Zhu YM Wang DZ Xu DM Tan CW Chen 2006 A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B Zhonghua Nei Ke Za Zhi 45 11 891 5 17313873 1:CAS:528:DC%2BD1cXis1Smsr4%3D (Chinese) Yao GB, Zhu M, Wang YM, Xu DZ, Tan DM, Chen CW, et al. A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B. Zhonghua Nei Ke Za Zhi. 2006;45(11):891–5 (Chinese).
101. 101. G. Yao 2007 Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China J Antimicrob Chemother 60 2 201 5 17556353 1:CAS:528:DC%2BD2sXos12mtr0%3D Yao G. Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. J Antimicrob Chemother. 2007;60(2):201–5.
102. 102. G Yao CW Chen WL Lu H Ren DM Tan YM Wang 2006 Entecavir achieves superior virologic response compared to lamivudine for the treatment of chronic hepatitis B: 2 year results from a phase 3 study in nucleoside-naïve patients in China Hepatology 44 Suppl 1 559A Yao G, Chen CW, Lu WL, Ren H, Tan DM, Wang YM, et al. Entecavir achieves superior virologic response compared to lamivudine for the treatment of chronic hepatitis B: 2 year results from a phase 3 study in nucleoside-naïve patients in China. Hepatology. 2006;44(Suppl 1):559A.
103. 103. H Senturk Y Lurie A Gadano 2007 ETV re-treatment of nucleoside-naïve HBeAg(-) patients J Hepatol 46 Suppl 1 S197 Senturk H, Lurie Y, Gadano A, et al. ETV re-treatment of nucleoside-naïve HBeAg(-) patients. J Hepatol. 2007;46(Suppl 1):S197.
104. 104. RJ Colonno R Rose CJ Baldick S Levine K Pakornowski CF Yu 2005 Entecavir resistance is rare in nucleoside naive patients with hepatitis B Hepatology 44 6 1656 65 [Comment in: Gut 2005;54(11):1521–3. Gut 2006;55(5):745; author reply 745–6.] Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology. 2006;44(6):1656–65. [Comment in: Gut. 2005;54(11):1521–3. Gut. 2006;55(5):745; author reply 745–6.]
105. 105. R Colonno R Rose K Pokornowski 2006 Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients Hepatology 44 Suppl 4 229A Colonno R, Rose R, Pokornowski K, et al. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients Hepatology. 2006;44(Suppl 4):229A.
106. 106. R Colonno R Rose K Pokornowski CJ Baldick B Eggers D Yu 2007 Four years assessment of entecavir resistance in nucleoside-naive and lamivudine refractory patients J Hepatol 46 Suppl 1 S294 Colonno R, Rose R, Pokornowski K, Baldick CJ, Eggers B, Yu D, et al. Four years assessment of entecavir resistance in nucleoside-naive and lamivudine refractory patients. J Hepatol. 2007;46(Suppl 1):S294.
107. 107. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130(7):2039–49.
108. 108. DJ Tenney RE Rose CJ Baldick SM Levine KA Pokornowski AW Walsh 2007 Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present Antimicrob Agents Chemother 51 3 902 11 17178796 1:CAS:528:DC%2BD2sXis12jsrk%3D Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother. 2007;51(3):902–11.
109. 109. H Simsek E Schiff Z Goodman H Brett-Smith K Klesczewski B. Kreter 2007 Efficacy of entecavir and lamivudine in chronic hepatitis B patients with advanced fibrosis/cirrhosis J Hepatol 46 Suppl 1 S197 Simsek H, Schiff E, Goodman Z, Brett-Smith H, Klesczewski K, Kreter B. Efficacy of entecavir and lamivudine in chronic hepatitis B patients with advanced fibrosis/cirrhosis J Hepatol. 2007;46(Suppl 1):S197.
110. 110. F Zoulim 2006 Entecavir: a new treatment option for chronic hepatitis B J Clin Virol 36 1 8 12 16515882 1:CAS:528:DC%2BD28Xjs1Khurw%3D Epub 2006 Mar 3. Review. Zoulim F. Entecavir: a new treatment option for chronic hepatitis B. J Clin Virol. 2006;36(1):8–12. Epub 2006 Mar 3. Review.
111. 111. Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis. 2006;26(2):162–70. Review.
112. 112. MA McMahon BL Jilek TP Brennan L Shen Y Zhou M Wind-Rotolo 2007 The HBV drug entecavir—effects on HIV-1 replication and resistance N Engl J Med 356 25 2614 21 17582071 1:CAS:528:DC%2BD2sXmslKjs7o%3D McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M, et al. The HBV drug entecavir—effects on HIV-1 replication and resistance. N Engl J Med. 2007;356(25):2614–21.
113. 113. CL Lai SG Lim NA Brown XJ Zhou DM Lloyd YM Lee MF Yuen GC Chao MW. Myers 2004 A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection Hepatology 40 3 719 26 15349912 1:CAS:528:DC%2BD2cXot1Ortb0%3D Lai CL, Lim SG, Brown NA, Zhou XJ, Lloyd DM, Lee YM, Yuen MF, Chao GC, Myers MW. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology. 2004;40(3):719–26.
114. 114. XJ Zhou SG Lim DM Lloyd GC Chao NA Brown CL. Lai 2006 Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications Antimicrob Agents Chemother 50 3 874 9 16495245 1:CAS:528:DC%2BD28XisFamtrc%3D Zhou XJ, Lim SG, Lloyd DM, Chao GC, Brown NA, Lai CL. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Antimicrob Agents Chemother. 2006;50(3):874–9.
115. 115. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129(2):528–36.
116. 116. J Rasenack T Poynard CL Lai E Gane N Brown EJ. Heathcoate 2007 Efficacy of telbivudine vs lamivudine at 2 years in patients with HBeAg-positive chronic hepatitis B who are eligible for treatment based on guidelines J Hepatol 46 Suppl 1 S195 Rasenack J, Poynard T, Lai CL, Gane E, Brown N, Heathcoate EJ. Efficacy of telbivudine vs lamivudine at 2 years in patients with HBeAg-positive chronic hepatitis B who are eligible for treatment based on guidelines. J Hepatol. 2007;46(Suppl 1):S195.
117. 117. E Gane CL Lai A Min J Heathcoate T Poynard OO Kurdas 2007 Adefovir salvage therapy for virologic breakthrough in telbivudine-treated patients from the GLOBE study J Hepatol 46 Suppl 1 S187 Gane E, Lai CL, Min A, Heathcoate J, Poynard T, Kurdas OO, et al. Adefovir salvage therapy for virologic breakthrough in telbivudine-treated patients from the GLOBE study. J Hepatol. 2007;46(Suppl 1):S187.
118. 118. T Poynard A Chutaputt SG Hwang SG Lim J Heathcoate YY Kuan 2007 Sustained off-treatment HBeAg response in telbivudine and lamivudine treated HBeAg-positive patients from the GLOBE study J Hepatol 46 Suppl 1 S27 Poynard T, Chutaputt A, Hwang SG, Lim SG, Heathcoate J, Kuan YY, et al. Sustained off-treatment HBeAg response in telbivudine and lamivudine treated HBeAg-positive patients from the GLOBE study. J Hepatol. 2007;46(Suppl 1):S27.
119. 119. P Marcellin HLY Chan CL Lai M Cho YM Moon YC Chao 2007 76 week follow up of HBeAg-positive chronic hepatitis B patients treated with telbivudine, adefovir or switch from adefovir to telbivudine J Hepatol 46 Suppl 1 S55 Marcellin P, Chan HLY, Lai CL, Cho M, Moon YM, Chao YC, et al. 76 week follow up of HBeAg-positive chronic hepatitis B patients treated with telbivudine, adefovir or switch from adefovir to telbivudine. J Hepatol. 2007;46(Suppl 1):S55.
120. 120. P Marcellin HLY Chan CL Lai M Cho J Heathcote YM Moon 2007 In hepatitis B patients treated with either adefovir or telbivudine, maximal early HBV suppression at 24 weeks predicts optimal one-year efficacy J Hepatol 46 Suppl 1 S193 Marcellin P, Chan HLY, Lai CL, Cho M, Heathcote J, Moon YM, et al. In hepatitis B patients treated with either adefovir or telbivudine, maximal early HBV suppression at 24 weeks predicts optimal one-year efficacy. J Hepatol. 2007;46(Suppl 1):S193.
121. 121. R Safadi Q Xie Y Chen YK Yin L Wei SG Hwang 2007 A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic hepatitis B: results of the primary analysis at week 24 J Hepatol 46 Suppl 1 S196 Safadi R, Xie Q, Chen Y, Yin YK, Wei L, Hwang SG, et al. A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic hepatitis B: results of the primary analysis at week 24. J Hepatol. 2007;46(Suppl 1):S196.
122. 122. Keam SJ. Telbivudine. Drugs. 2007;67(13):1917–29 (Review).
123. 123. CA Brown F Smith KA. Laessig 2007 Creatine kinase (CK) elevations and muscle toxicity associated with chronic telbivudine (LdT) use in prospective clinical trials Hepatology 46 4 Suppl 1 655A Brown CA, Smith F, Laessig KA. Creatine kinase (CK) elevations and muscle toxicity associated with chronic telbivudine (LdT) use in prospective clinical trials. Hepatology. 2007;46(4 Suppl 1):655A.
124. 124. Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med. 2006;166(1):49–56. [Comment in: Arch Intern Med. 2006;166(1):9–12.]
125. 125. BE Korba PJ Cote S Menne I Toshkov BH Baldwin FV Wells 2004 Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection Antivir Ther 9 6 937 52 15651753 1:CAS:528:DC%2BD2MXhtFahtbs%3D Korba BE, Cote PJ, Menne S, Toshkov I, Baldwin BH, Wells FV, et al. Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection Antivir Ther. 2004;9(6):937–52.
126. 126. BE Korba PA Furman MJ Otto 2006 Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo Expert Rev Anti Infect Ther 4 4 549 61 17009935 1:CAS:528:DC%2BD28XhtVCnt7bL (review) Korba BE, Furman PA, Otto MJ. Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo. Expert Rev Anti Infect Ther. 2006;4(4):549–61 (review).
127. 127. HS Lee YH Chung K Lee KS Byun SW Paik JY Han 2006 A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B Hepatology 43 5 982 8 16628625 1:CAS:528:DC%2BD28XkvFGmt7k%3D Lee HS, Chung YH, Lee K, Byun KS, Paik SW, Han JY, et al. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology. 2006;43(5):982–8.
128. 128. BC Yoo JH Kim TH Kim KC Koh SH Um YS Kim 2007 Clevudine is highly efficacious in hepatitis Be antigen-negative chronic hepatitis B with durable off-therapy viral suppression Hepatology 46 4 1041 8 17647293 1:CAS:528:DC%2BD2sXht1aksr3J Yoo BC, Kim JH, Kim TH, Koh KC, Um SH, Kim YS, et al. Clevudine is highly efficacious in hepatitis Be antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology. 2007;46(4):1041–8.
129. 129. BC Yoo JH Kim YH Chung KS Lee SW Paik SH Ryu 2007 Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B Hepatology 45 5 1172 8 17464992 1:CAS:528:DC%2BD2sXlslOju7w%3D Yoo BC, Kim JH, Chung YH, Lee KS, Paik SW, Ryu SH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology. 2007;45(5):1172–8.
130. 130. KS Lee KS Byun YH Chung SW Paik JY Han K Yoo 2007 Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy Intervirology 50 4 296 302 17622789 1:CAS:528:DC%2BD2sXotVaitbw%3D Lee KS, Byun KS, Chung YH, Paik SW, Han JY, Yoo K, et al. Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy. Intervirology. 2007;50(4):296–302.
131. 131. SG Lim Z Krastev TM Ng G Mechkov IA Kotzev S Chan 2006 Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B Antimicrob Agents Chemother 50 5 1642 8 16641430 1:CAS:528:DC%2BD28XksVKktrs%3D Lim SG, Krastev Z, Ng TM, Mechkov G, Kotzev IA, Chan S, et al. Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob Agents Chemother. 2006;50(5):1642–8.
132. 132. F Bömmel van B Zöllner C Sarrazin U Spengler D Hüppe B Möller 2006 Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy Hepatology 44 2 318 25 16871563 [Comment in: Hepatology. 2006;44(2):309–13.] van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006;44(2):318–25. [Comment in: Hepatology. 2006;44(2):309–13.]
133. 133. F Bömmel van RA Man De A Erhardt D Huppe K Stein P Buggisch 2007 First multicenter evaluation of the efficacy of tenofovir in nucleos(t)ide analog experienced patients with HBV monoinfection Hepatology 46 4 Suppl 1 270A van Bömmel F, De Man RA, Erhardt A, Huppe D, Stein K, Buggisch P, et al. First multicenter evaluation of the efficacy of tenofovir in nucleos(t)ide analog experienced patients with HBV monoinfection. Hepatology. 2007;46(4 Suppl 1):270A.
134. 134. P Marcellin M Buti Z Krastev G Germanidis KD Kaita I Kotzev 2007 A randomized, double-blind, comparison of tenofovir DF (TDF) for the treatment of HBeAg-negative chronic hepatitis B (CHB): study GS-US-174–0102 Hepatology 46 4 Suppl 1 80A Marcellin P, Buti M, Krastev Z, Germanidis G, Kaita KD, Kotzev I, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) for the treatment of HBeAg-negative chronic hepatitis B (CHB): study GS-US-174–0102. Hepatology. 2007;46(4 Suppl 1):80A.
135. 135. EJ Heathcoate E Gane R Man De S Lee R Flisiak MP Mann 2007 A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-positive chronic hepatitis B (CHB): study GS-US-174–0103 Hepatology 46 4 Suppl 1 861A Heathcoate EJ, Gane E, De Man R, Lee S, Flisiak R, Mann MP, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-positive chronic hepatitis B (CHB): study GS-US-174–0103. Hepatology. 2007;46(4 Suppl 1):861A.